GT200900236A - Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopopril-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden esta formas.- - Google Patents
Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopopril-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden esta formas.-Info
- Publication number
- GT200900236A GT200900236A GT200900236A GT200900236A GT200900236A GT 200900236 A GT200900236 A GT 200900236A GT 200900236 A GT200900236 A GT 200900236A GT 200900236 A GT200900236 A GT 200900236A GT 200900236 A GT200900236 A GT 200900236A
- Authority
- GT
- Guatemala
- Prior art keywords
- phenyl
- acid
- polymorphes
- morfolin
- isoxazol
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000004677 hydrates Chemical class 0.000 title abstract 2
- 101710113864 Heat shock protein 90 Proteins 0.000 abstract 2
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical class CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 229940095064 tartrate Drugs 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A NUEVAS FORMAS DE SAL DE ETIL-AMIDA DEL ÁCIDO 5-(2,4-DIHIDROXI-5-ISOPROPIL-FENIL)-4-(4-MORFOLIN-4-IL-METIL-FENIL)-ISOXAZOL-3-CARBOXÍLICO, EN PARTICULAR LA SAL DE MESILATO, CLORHIDRATO, TARTRATO, FOSFATO Y HEMI-FUMARATO DE LA MISMA, A FORMAS CRISTALINAS DE ESTAS SALES, A POLIMORFOS DE ETIL-AMIDA DEL ÁCIDO 5-(2,4-DIHIDROXI-5-ISOPROPIL-FENIL)-4-(4-MORFOLIN-4-IL-METIL-FENIL)-ISOXAZOL-3-CARBOXÍLICO; A HIDRATOS Y POLIMORFOS DE LAS NUEVAS FORMAS DE SAL MENCIONADAS ANTERIORMENTE, PARA LA FABRICACIÓN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE UN TRASTORNO MEDIADO POR HSP90, A UN MÉTODO PARA EL TRATAMIENTO DE UN TRASTORNO MEDIADO POR HSP90, UTILIZANDO LAS NUEVAS FORMAS DE SAL; A FORMULACIONES QUE COMPRENDEN ESTAS FORMAS DE SAL, EN PARTICULAR SOLUCIONES ACUOSAS ADECUADAS PARA ADMINISTRACIÓN INTRAVENOSA; Y A RECIPIENTES DE VIDRIO ÁMBAR QUE SE RELLENAN CON ESTAS FORMULACIONES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07103346 | 2007-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT200900236A true GT200900236A (es) | 2011-09-14 |
Family
ID=38134307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200900236A GT200900236A (es) | 2007-03-01 | 2009-08-31 | Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopopril-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden esta formas.- |
Country Status (40)
| Country | Link |
|---|---|
| US (3) | US8163747B2 (es) |
| EP (2) | EP2545921A3 (es) |
| JP (1) | JP2010520176A (es) |
| KR (1) | KR20090122218A (es) |
| CN (2) | CN102302500A (es) |
| AR (1) | AR065519A1 (es) |
| AT (1) | ATE552836T1 (es) |
| AU (1) | AU2008220800B2 (es) |
| BR (1) | BRPI0807992A2 (es) |
| CA (1) | CA2678043A1 (es) |
| CL (1) | CL2008000618A1 (es) |
| CO (1) | CO6210828A2 (es) |
| CR (1) | CR10989A (es) |
| CY (1) | CY1113805T1 (es) |
| DK (1) | DK2131845T3 (es) |
| DO (1) | DOP2009000209A (es) |
| EA (1) | EA017075B1 (es) |
| EC (1) | ECSP099602A (es) |
| ES (1) | ES2384906T3 (es) |
| GE (1) | GEP20115309B (es) |
| GT (1) | GT200900236A (es) |
| HR (1) | HRP20120535T1 (es) |
| IL (1) | IL200401A0 (es) |
| MA (1) | MA31204B1 (es) |
| MX (1) | MX2009009233A (es) |
| NI (1) | NI200900161A (es) |
| NZ (1) | NZ578854A (es) |
| PA (1) | PA8771101A1 (es) |
| PE (1) | PE20090166A1 (es) |
| PL (1) | PL2131845T3 (es) |
| PT (1) | PT2131845E (es) |
| RS (1) | RS52351B (es) |
| SI (1) | SI2131845T1 (es) |
| SM (1) | SMAP200900080A (es) |
| TN (1) | TN2009000357A1 (es) |
| TW (1) | TW200844102A (es) |
| UA (1) | UA101950C2 (es) |
| UY (1) | UY30943A1 (es) |
| WO (1) | WO2008104595A1 (es) |
| ZA (1) | ZA200905417B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200922595A (en) * | 2007-10-12 | 2009-06-01 | Novartis Ag | Organic compounds |
| TWI450898B (zh) * | 2008-07-04 | 2014-09-01 | Sigma Tau Res Switzerland Sa | 具有抗腫瘤活性之芳基異唑化合物 |
| WO2010060854A1 (en) | 2008-11-25 | 2010-06-03 | Nerviano Medical Sciences S.R.L. | Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents |
| DK2525796T3 (en) * | 2010-01-21 | 2016-07-04 | Aprea Ab | An aqueous solution comprising 3-quinuclidinoner for the treatment of hyperproliferative disease, autoimmune disease and heart disease |
| US20120309750A1 (en) * | 2010-02-17 | 2012-12-06 | Ildong Pharm Co., Ltd. | 5-membered heterocycle derivatives and manufacturing process thereof |
| KR20120031854A (ko) | 2010-09-27 | 2012-04-04 | 한국전자통신연구원 | 시간 및 주파수 특징을 이용하는 음악 음원 분리 장치 및 방법 |
| WO2013015661A2 (en) * | 2011-07-28 | 2013-01-31 | Ildong Pharm Co.,Ltd. | Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide |
| FR3039401B1 (fr) * | 2015-07-31 | 2018-07-13 | Les Laboratoires Servier | Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA009919B1 (ru) * | 2003-02-11 | 2008-04-28 | Вернэлис (Кембридж) Лимитед | Соединения изоксазола |
| US20060070405A1 (en) * | 2004-10-06 | 2006-04-06 | Anheuser-Busch, Inc. | Method for the production of amber glass with reduced sulfur-containing emissions |
| EP2491923A3 (en) | 2007-02-15 | 2012-12-26 | Novartis AG | Combinations of therapeutic agents for treating cancer |
| WO2010069458A1 (de) | 2008-12-17 | 2010-06-24 | Merck Patent Gmbh | Hexahalochromat(lll)-komplexe |
-
2008
- 2008-02-28 JP JP2009551218A patent/JP2010520176A/ja active Pending
- 2008-02-28 AR ARP080100831A patent/AR065519A1/es not_active Application Discontinuation
- 2008-02-28 SI SI200830688T patent/SI2131845T1/sl unknown
- 2008-02-28 AU AU2008220800A patent/AU2008220800B2/en not_active Ceased
- 2008-02-28 PT PT08717228T patent/PT2131845E/pt unknown
- 2008-02-28 UY UY30943A patent/UY30943A1/es not_active Application Discontinuation
- 2008-02-28 EA EA200901141A patent/EA017075B1/ru not_active IP Right Cessation
- 2008-02-28 CA CA002678043A patent/CA2678043A1/en not_active Abandoned
- 2008-02-28 CN CN201110226727.8A patent/CN102302500A/zh active Pending
- 2008-02-28 WO PCT/EP2008/052443 patent/WO2008104595A1/en not_active Ceased
- 2008-02-28 PL PL08717228T patent/PL2131845T3/pl unknown
- 2008-02-28 CN CN200880005490.7A patent/CN101636162A/zh active Pending
- 2008-02-28 EP EP11192158.1A patent/EP2545921A3/en not_active Withdrawn
- 2008-02-28 UA UAA200908592A patent/UA101950C2/ru unknown
- 2008-02-28 KR KR1020097018126A patent/KR20090122218A/ko not_active Ceased
- 2008-02-28 HR HRP20120535AT patent/HRP20120535T1/hr unknown
- 2008-02-28 US US12/529,090 patent/US8163747B2/en active Active
- 2008-02-28 GE GEAP200811444A patent/GEP20115309B/en unknown
- 2008-02-28 NZ NZ578854A patent/NZ578854A/en not_active IP Right Cessation
- 2008-02-28 AT AT08717228T patent/ATE552836T1/de active
- 2008-02-28 RS RS20120263A patent/RS52351B/sr unknown
- 2008-02-28 MX MX2009009233A patent/MX2009009233A/es active IP Right Grant
- 2008-02-28 ES ES08717228T patent/ES2384906T3/es active Active
- 2008-02-28 DK DK08717228.4T patent/DK2131845T3/da active
- 2008-02-28 BR BRPI0807992-7A2A patent/BRPI0807992A2/pt not_active IP Right Cessation
- 2008-02-28 EP EP08717228A patent/EP2131845B1/en active Active
- 2008-02-29 PE PE2008000418A patent/PE20090166A1/es not_active Application Discontinuation
- 2008-02-29 PA PA20088771101A patent/PA8771101A1/es unknown
- 2008-02-29 TW TW097107239A patent/TW200844102A/zh unknown
- 2008-02-29 CL CL200800618A patent/CL2008000618A1/es unknown
-
2009
- 2009-08-03 ZA ZA200905417A patent/ZA200905417B/xx unknown
- 2009-08-13 IL IL200401A patent/IL200401A0/en unknown
- 2009-08-21 CR CR10989A patent/CR10989A/es not_active Application Discontinuation
- 2009-08-28 TN TNP2009000357A patent/TN2009000357A1/fr unknown
- 2009-08-28 NI NI200900161A patent/NI200900161A/es unknown
- 2009-08-28 EC EC2009009602A patent/ECSP099602A/es unknown
- 2009-08-31 GT GT200900236A patent/GT200900236A/es unknown
- 2009-08-31 MA MA32191A patent/MA31204B1/fr unknown
- 2009-08-31 DO DO2009000209A patent/DOP2009000209A/es unknown
- 2009-09-01 CO CO09092694A patent/CO6210828A2/es not_active Application Discontinuation
- 2009-09-30 SM SM200900080T patent/SMAP200900080A/it unknown
-
2012
- 2012-03-08 US US13/415,268 patent/US8487095B2/en not_active Expired - Fee Related
- 2012-07-09 CY CY20121100610T patent/CY1113805T1/el unknown
-
2013
- 2013-07-10 US US13/938,659 patent/US20130296556A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT200900236A (es) | Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopopril-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden esta formas.- | |
| CO6680698A2 (es) | Formulación de premezcla de dexmedetomidina | |
| BR112014026651A8 (pt) | derivados de imidazotiadiazol e de imidazopiridazina como inibidores do receptor ativado por proteases 4 (par4) para o tratamento de agregação plaquetária | |
| MX2018000179A (es) | Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida. | |
| CL2012002318A1 (es) | Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer. | |
| UA124922C2 (uk) | Модулятори ядерного транспорту та їх застосування | |
| CO6612271A2 (es) | Anticuerpos anti-cd40 | |
| CO6480931A2 (es) | Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas. | |
| BR112015018168A2 (pt) | inibidores de rock suaves | |
| UA109290C2 (uk) | Спільні кристали і солі інгібіторів ccr3 | |
| BR112015007647A2 (pt) | derivados de quetamina | |
| EA201270071A1 (ru) | Способ лечения пациента, нуждающегося в аспириновой терапии | |
| CY1125224T1 (el) | Κρυσταλλικες μορφες 1-(3-τριτ-βουτυλο-1-ρ- τολυλο-1η-πυραζολ-5-υλο)-3-(5-φθορο-2-(1-(2- υδροξυαιθυλ)-ινδαζολ-5-υλοξυ)βενζυλ)ουριας υδροχλωρικη | |
| CL2015003468A1 (es) | Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d. | |
| BR112013033831A2 (pt) | composição farmacêutica oftalmológica tópica que contém regorafenib | |
| GT200800235A (es) | Formulacion de medicamento liquida | |
| BR112014004732A2 (pt) | composto benzotiazolona | |
| CL2015001940A1 (es) | Formulación que comprende un compuesto de benzotiazolona. | |
| MX2019011386A (es) | Compuestos, composiciones farmaceuticas y un metodo para la profilaxis y tratamiento del proceso de adhesion. | |
| CL2008003584A1 (es) | Uso de la 10-[(3r)-1-azabiciclo]oct-3-ilmetil]-10-h-fenotiazina, o una de sus sales farmaceuticamente aceptables para la preparación de un medicamento util para prevenir o tratar la bronconeumopatia obstructiva. | |
| MX2022015232A (es) | Composicion farmaceutica acuosa de levilimab y su uso. | |
| AR100153A1 (es) | Medicamento | |
| AR089764A1 (es) | Composicion farmaceutica de administracion oral de nitazoxanida, util para el tratamiento de infecciones parasitarias intestinales, y proceso para preparar granulos para suspension de nitazoxanida | |
| EA200702295A1 (ru) | Применение азитромицина для изготовления лекарственного средства для лечения глазных инфекций | |
| UA71558U (ru) | Способ лечения заболеваний тканей пародонта у больных метаболическим синдромом |